We used PF-4708671, which is a highly specific inhibitor of S6K1 and of benefit in several neurological disorders, to conduct the current study (Hayashi et al., 2016; Pearce et al., 2010; Srivastava et al., 2016). This evidence concerns the gene RPS6KB1 and nervous system disorder.